Cancer Therapeutics Market

Cancer Therapeutics Market Overview

The global Cancer Therapeutics Market size was valued at USD 189.79 billion in 2024 and is predicted to reach USD 326.05 billion by 2034 with a CAGR of 9.4% from 2025-2030.

The cancer treatment market is driven by the rising prevalence of chronic diseases among individuals, growing aging population and technological advancement in oncology department around the world. However, the oncology therapy market possesses some growth challenges such as, high cost associated with cancer therapies that slows the overall growth of the market as many people are unable to avail these therapies due to the financial constrain. 

On the contrary, adoption of next-generation antibody-drug conjugates (ADCs) projected to create future growth opportunity for the market. Additionally, the major players in the market include Novartis AG and AbbVie are adopting various business strategies such as product launch and acquisition in order in enhance market expansion and broaden their product offering. With the advancement in personalized medicine, the market is set for constant growth as this will enable individuals to modify therapies as per their body needs.

Rising Prevalence of Chronic Diseases Boost Market Growth 

The increasing prevalence of chronic conditions namely cancer and tumours across the globe is stimulating the demand for effective treatment such as cancer therapeutics to manage and treat such impending health concerns. Based on the report published by World Health Organisation, there were approximately 20 million new cases of cancer and 9.7 million cancer deaths in 2023. With such an increase in cancer cases all over the globe the demand for effective treatments such as cancer therapies is growing, hence driving the market growth.

Aging Population Fuels the Cancer Therapeutics Market Growth

The rapidly growing elderly population across the globe along with the rise in health issues including cancer drives the demand for cancer therapeutics. As people grow older the risk of developing cancer is on rise driving the demand for effective treatment to effectively manage and treat these conditions. 

According to the latest reports published by Union for International Cancer Control, 53% of people suffering from cancer are within the age of 65 years and above and for every one young person diagnosed with cancer, 11 older people are diagnosed as well. These rises in cases of cancer especially among elderly persons across the world puts into for right treatment for such diseases.

Technological Advancements for Cancer Treatments Boosts Market Growth

The development of the cancer therapeutics market trends is pushed by terminal therapies, immunotherapy, and targeted medicine along with other technological advances in cancer care. The technologies improve the effectiveness of the therapy, reduce the side effects, and offers individualized responses to the specific needs of the patients. 

For example, in February 2024, Johnson & Johnson’s Carvykti, blood cancer therapy got approval from the FDA to use a bi-weekly dosing schedule that offers the convenience of multiple myeloma patients, relapsed or refractory. The new dosing plan improves patient compliance and the use of CAR-T cell treatment supporting the growth of this sector. 

High Cost for Treatments Restrains the Market Growth

The cancer therapeutics market demand is limited by the high expense of the cancer treatments including chemotherapy, targeted therapies, and immunotherapy. This financial burden restricts accessibility, especially in low-and middle-income nations, where healthcare infrastructure and insurance coverage are limited. 

Adoption of Next-Generation Antibody Drug Conjugates (ADCs) Creates Future Growth Opportunities for the Market

Adoption of next-generation antibody-drug conjugates (ADCs) projected to revolutionize the market for cancer therapeutics with highly targeted, more potent and less toxic therapies. In contrast to, traditional chemotherapy, these new ADCs deliver cytotoxin agents with pinpoint accuracy to cancer cells and spare healthy tissue, with a much higher efficacy and lower side effects.

Market Segmentations and Scope of the Study 

The cancer therapeutics market report is segmented on the basis of therapy type, cancer type, end-user, and region. On the basis of therapy type, the market is segmented into chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and others. On the basis of by cancer type, the market is classified into blood cancer, breast cancer, prostate cancer, gastrointestinal cancer, gynaecologic cancer, respiratory/lung cancer, and others. Based on key drug, the market is segmented into, keytruda, darzalex, revlimid, avastin, herceptin and others.  On the basis of end-user, the market is segmented into hospitals, specialty clinics, and cancer & radiation therapy centers. Regional breakdown and analysis of each of the aforesaid segments includes regions comprising of North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis

North America dominates the cancer therapeutics market share is expected to maintain this position during the forecast period due to the rising occurrence of chronic conditions including cancer. The increasing prevalence of cancer led to significant advancements in treatment options including targeted therapies, immunotherapies, and precision medicine. As per the latest report published by the American Cancer Society, in U.S. the total of cancer cases accounted for 1.9 million in 2023 that caused over 0.6 million deaths.

Therefore, the increase in cancer patients requires advanced treatment facility with cancer therapies and vaccines to handle such an incidence and for the health of the people. 

Moreover, the growing aging population in this region is driving the cancer drug development, as older adults face a higher risk of developing cancer due to weakened immune system. According to latest reports published by CIHR Institute of Aging Strategic Plan, currently Canadian population consists of nearly 19% of aged population that sums to 7 million in 2023. As life expectancy increases, ensuring accessible and effective cancer treatments for the aging population will be crucial in shaping the future of oncology care. 

On the other hand, Asia-Pacific region shows a steady rise in cancer therapeutics industry during the forecast period. This is attributed towards the government schemes that seeks to enhance the efficiency of healthcare in reaching out all sector of the country. 

According to the report of the of Ministry of Commerce and Industry, the Indian government introduced program to be known as Ayushman Bharat Pradhan Mantri Jan Arogya Yojana. The government strategy is that the needy persons of health of the country should be in a position to pay for health insurance for some diseases that includes cancer as well. 

Furthermore, the market is the region is developing at an extremely high speed with massive investment from the public and private sector in medical R&D. National Bureau of Statistics (NBS) 2025 indicated that China's aggregate R&D expenditure exceeded USD 500 billion in 2024 with an 8.3% growth compared to last year. This spending accounted for 2.68% of the country's GDP that is 0.1 % points more than in 2023. These investments are powering innovation in immunotherapy and precision medicine with the private sector playing an increasing role in clinical trials and novel treatments.

Competitive Landscape

Various market players operating in the cancer therapeutics industry are as F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson, Sanofi, Astellas Pharma Inc., Pfizer Inc., Novartis AG, Merck KGaA, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., AstraZeneca, Gilead Sciences, Inc., Incyte and others. These market players are adopting various strategies such as product launches and acquisition to remain dominant in the market. 

For instance, in June 2024, AbbVie launched CERVINO that is a Phase 3 trial to assess the efficacy of ABBV-383, BCMA/CD3 bispecific antibody agent in treating relapsed multiple myeloma. The trial seeks to find out whether ABBV-383 is more favorable for patients who failed at least two previous lines of treatment.

Moreover, in May 2024, Novartis acquired Mariana Oncology to focus on developing novel radioligand therapies pipeline for treating cancers. In this particular regard, this acquisition demonstrates Novartis’s focus on driving the evolution of next-generation RLTs’ enrolment and its growth in oncology research and clinical supply. 

Additionally, in January 2024, Roche AG received European Commission approval for a subcutaneous formulation, providing a faster and more convenient administration option for cancer patients. Compared to new subcutaneous formulation, similar efficacy and safety profile but decreases time of treatment after intravenous infusion from thirty to sixty minutes to approximately seven minutes. 

Key Benefits

• The report provides quantitative analysis and estimations of the cancer therapeutics market from 2025 to 2030, which assists in identifying the prevailing market opportunities.

• The study comprises a deep-dive analysis of cancer treatment Market including the current and future trends to depict prevalent investment pockets in the market.

• Information related to key drivers, restraints, and opportunities and their impact on the cancer therapeutics market is provided in the report. 

• Competitive analysis of the players, along with their market share is provided in the report.

• SWOT analysis and Porters Five Forces model is elaborated in the study.

• Value chain analysis in the market study provides a clear picture of roles of stakeholders.

Cancer Therapeutics Market Key Segments

By Therapy Type

• Chemotherapy

• Targeted Therapy

• Immunotherapy

• Hormonal Therapy

• Others

By Cancer Type

• Blood Cancer

• Breast Cancer

• Prostate Cancer

• Gastrointestinal Cancer

• Gynecologic Cancer

• Respiratory/Lung Cancer

• Others

By Key Drug

• Keytruda

• Darzalex

• Revlimid

• Avastin

• Herceptin

• Others

By End Users

• Hospitals

• Specialty Clinics

• Cancer & Radiation Therapy Centers

By Region

• North America

  • The U.S.

  • Canada

  • Mexico

• Europe

  • The UK

  • Germany

  • France        

  • Italy        

  • Spain        

  • Denmark        

  • Netherlands        

  • Finland        

  • Sweden        

  • Norway        

  • Russia

  • Rest of Europe

• Asia-Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Indonesia

  • Singapore

  • Taiwan

  • Thailand

  • Rest of Asia-Pacific 

• RoW

  • Latin America

  • Middle East 

  • Africa

Key Players

• F. Hoffmann-La Roche AG

• Bristol-Myers Squibb Company

• AbbVie Inc.

• Johnson & Johnson

• Sanofi

• Astellas Pharma Inc.

• Pfizer Inc.

• Novartis AG

• Merck KGaA

• Eli Lilly and Company

• Takeda Pharmaceutical Company Limited

• Regeneron Pharmaceuticals Inc.

• AstraZeneca

• Gilead Sciences, Inc.

• Incyte

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Market Size in 2024	USD 189.79 billion
Revenue Forecast in 2030	USD 326.05 billion
Growth Rate	CAGR of 9.4% from 2025 to 2030
Analysis Period	2024–2030
Base Year Considered	2024
Forecast Period	2025–2030
Market Size Estimation	Billion (USD)
Growth Factors	Increasing chronic diseases drives demand for cancer therapeutics industry. Rapidly growing ageing population fuels the market growth. Technological advancements boost market growth for cancer therapeutics.
Countries Covered	28
Companies Profiled	15
Market Share	Available for 10 companies
Customization Scope	Free customization (equivalent to up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.